Company intelligence / Profile preview

Taiyo Pharma

Ownership: Private
Employees: ~500
Development stage: Other

Overview

Taiyo operates globally as a leading CDMO/CMO with decades of experience in high-quality pharmaceutical production. It manufactures generic drugs—including vitamins and antibiotics—and has expanded into advanced modalities like pre-filled syringes for vaccines and parenterals. The company is also investing in regenerative medicine and gene therapy capabilities.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeBiologicGene therapyRegenerative medicine
Industry: Contract Manufacturing Organization

Partnerships

Joint ventures such as TMT Co., Ltd. with Microwave Chemical Co., Ltd.Partnerships with Daiichi Sankyo Group legacy facilitiesVarious global pharma clients via CDMO services

Beyond the preview

Go deeper on Taiyo Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taiyo Pharma.

Explore the full profile